Understanding Immunotherapy Discussions
This study is looking into how patients and healthcare providers talk about immunotherapy, a type of cancer treatment that uses your body's immune system. We want to understand what patients already know about immunotherapy, where they get their information, and how doctors explain it. We're also testing if educational videos can help patients better understand this treatment. The goal is to improve how information is shared so patients can make informed decisions. This study is open to patients with blood cancers (Hematopoietic and Lymphoid System Neoplasm) or solid tumors (Malignant Solid Neoplasm) who are discussing immunotherapy at the Winship Cancer Institute, as well as any cancer patient for one part of the study. We aim to enroll 125 participants, but the current recruitment status is unclear.
- Study design
- This interventional study plans to enroll 125 participants. It involves testing an educational video, conducting interviews, and observing patient-provider conversations.
- What's involved
- You would undergo observation during a conversation about immunotherapy, participate in a 20-minute interview, and then have your understanding of educational videos tested.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your understanding and preferences will be assessed for up to 4 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Communication Issues in Patient and Provider Discussions of Immunotherapy
At a glance
Conditions
NCT05873608
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Atlanta VA Medical Center
Decatur, Georgiastudy coordinator listed
Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Rebecca Pentz, PhD · PRINCIPAL_INVESTIGATOR · Emory University Hospital/Winship Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Misestimations about the risks and benefits of immunotherapy resulting from media hype or other sourcesUp to 4 years
Will use descriptive statistics to summarize the demographic characteristics and responses to the interviews. Will audio-record and transcribe the provider conversation for immunotherapy and the pre- and post-provider conversation interviews. The transcripts will be qualitatively coded using multi-level semantic analysis in MAXQDA. Pre-determined codes will include a list of potential benefits of immunotherapy, any patient estimation of the potential for benefit, any side effect and risk mentioned and any estimation of its frequency. Because there is no data on the frequency of misestimations due to media hype, no quantitative analysis is planned.
- Qualitatively describe patient reported misunderstandingsUp to 4 years
During the observed conversation, the ethics team member will note any technical term or metaphor used. The patient will then be asked if each term and metaphor is understood. The open ended questions about misunderstanding, technical terms and metaphors used, and patients' understanding of each term will be qualitatively coded using multi-level semantic analysis in MAXQDA. Frequency of misunderstood terms and misunderstood metaphors will be calculated.
- Provider and patient preferences for information to be communicated about immunotherapyUp to 4 years
The frequencies of each item of information identified by providers and patients will be determined. A combined list of the most frequently mentioned items of information to be included and a discussion of immunotherapy will be compiled.
- Correct definition rates (pre- versus post-video)Up to 4 years
Before-video and after-video correct definition rates will be calculated, along with 95% exact binomial confidence intervals using the Clopper-Pearson method. Before and after paired rates will be compared using an exact McNemar's test. Subset analyses will be performed for gender, age group (=\< 55, \> 55), and education level (high school graduate or less, some college or more).